Literature DB >> 19095097

Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome?

Susanne Carpenter1, Barbara Pockaj, Amylou Dueck, Richard Gray, David Kurtz, Aleksander Sekulic, William Casey.   

Abstract

BACKGROUND: Whether time between biopsy and surgery for malignant melanoma affects clinical outcomes is sparsely defined. This study evaluated factors influencing surgical interval and surgical interval effect on outcomes.
METHODS: We performed a review of a prospective 10-year, single-institution database.
RESULTS: There were 473 patients treated for 478 malignant melanomas. The mean surgical interval was 30.5 days. The mean thickness was 2.1 mm; 46% of patients had a surgical interval of more than 28 days whereas 8% had a surgical interval of more than 56 days. Residual melanoma was found at excision in 170 (36%) patients. Age, sex, and referral source significantly affected surgical interval, however, lesion thickness, sentinel lymph node status, ulceration, and residual melanoma at excision did not. In univariate Cox models, neither a surgical interval of 28 or less nor less than 56 days showed better overall survival (OS) or disease-free survival (DFS). In multivariate Cox models of OS and DFS including lesion thickness, sentinel lymph node status, ulceration, and residual melanoma at excision, neither a surgical interval of 28 days or fewer nor a surgical interval of 56 days or fewer significantly affected outcomes.
CONCLUSIONS: Age, sex, referral source, and lesion thickness were associated with surgical interval. Immediate surgery for malignant melanoma does not significantly impact OS or DFS.

Entities:  

Mesh:

Year:  2008        PMID: 19095097     DOI: 10.1016/j.amjsurg.2008.07.044

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

1.  Malignant melanoma: factors affecting the surgical interval from excision biopsy to definitive surgical management.

Authors:  M R Boland; R S Prichard; G A Bass; Z Al-Hilli; A Levendale; D Gibbons; K Sheahan; B Kirby; E W McDermott; D Evoy
Journal:  Ir J Med Sci       Date:  2014-06-11       Impact factor: 1.568

2.  Determination of the impact of melanoma surgical timing on survival using the National Cancer Database.

Authors:  Ruzica Z Conic; Claudia I Cabrera; Alok A Khorana; Brian R Gastman
Journal:  J Am Acad Dermatol       Date:  2017-10-17       Impact factor: 11.527

3.  Association of Delays in Surgery for Melanoma With Insurance Type.

Authors:  Adewole S Adamson; Lei Zhou; Christopher D Baggett; Nancy E Thomas; Anne-Marie Meyer
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

4.  Defining an acceptable period of time from melanoma biopsy to excision.

Authors:  Laura S Huff; Caroline A Chang; Jacob F Thomas; Margaret Cook-Shimanek; Paul Blomquist; Nellie Konnikov; Robert P Dellavalle
Journal:  Dermatol Reports       Date:  2012-01-17

Review 5.  Controversies in the diagnosis and treatment of early cutaneous melanoma.

Authors:  O A Orzan; A Șandru; C R Jecan
Journal:  J Med Life       Date:  2015 Apr-Jun

6.  What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer.

Authors:  Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore
Journal:  Clin Oncol Res       Date:  2020-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.